References
- ASHFORTH, E. I. L., CARLILE, D. J., C HENERY, R. and HOUSTON, J. B., 1995, Prediction of in vivo disposition from in vitro system : clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. Journal of Pharmacology and Experimental Therapeutics, 274, 761–766.
- AUDHUY, B., CAPPELAERE, P., MARTIN, M., CERVANTES, A., FABBRO, M., RIVIERE, A., K HAYAT D., B LEIBERG, H., FARALDI M. and C LAVERIE, N., 1996, A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. European Journal of Cancer, 32A, 807–813.
- BAARNHIELM, C., D AHLBACK, H. and S KANBERG, I., 1986, In vitro pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacologica et Toxicologicd 59, 113–122.
- BOEIJINGA, P. H., G ALVAN, M ., BARON, B. M., D UDLEY M W S IEGEL, B. W. and S TONE, A. L., 1992, Characterization of the novel 5-HT 3 receptor antagonist MDL 73,147EF (Dolasetron mesilate) and MDL 74,156 in NG 108–15 neuroblastoma X glioma cells. European Journal of Pharmacology, 219, 9–13.
- BOXENBAUM, H. 1982, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 10, 201–227.
- BOXENBAUM, H., 1984, Interspecies pharmacokinetic scaling and the evolutionary-comparative para-digm. Drug Metabolism Reviews, 15, 1071–1121.
- BOXENBAUM, H. and D'S OUZA, R. W., 1990, Interspecies pharmacokinetic scaling, biological design and neotensy. In Advances in Drug Research, edited by B. Testa (London: Academic), pp. 139–196.
- BOXENBAUM, H. and DI LEA, C., 1995, First- time- in-human dose selection: allometric thoughts and perspectives. Journal of Clinical Pharmacology, 35, 957–966.
- BOXENBAUM, H. and FERTIG, J. B., 1984, Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. European Journal of Drug Metabolism and Pharmacokinetics, 9, 177–183.
- BOXENBAUM, H., G ILLESP1E, T., HECK, K. and H AHNE, W., 1992, Human dolasetron pharmacokinetics: I. Disposition following single dose intravenous administration to normal male subjects. Biopharmaceutics and Drug Disposition, 13, 693–701.
- BOXENBAUM, H., G ILLESP1E, T., HECK, K. and H AHNE, W., 1993, Human dolasetron pharmacokinetics: II. Absorption and disposition following single dose oral administration to normal male subjects. Biopharmaceutics and Drug Disposition, 14, 131–141.
- CHIBA, M., FUJITA, S. and Suzum, T., 1990, Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. Journal of Pharmaceutical Sciences, 79, 281–287.
- CRUZE, C. A., KM, G. R. and MEREDITH, M. P., 1995, Interspecies scaling of tebufelone pharmaco-kinetic data and application to preclinical toxicology. Pharmaceutical Research, 12, 895–901.
- DAVIES, B. and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093–1095.
- DEDRICK, R. L., B ISCHOFF, K. B. and ZAHARKO, D. S., 1970, Interspecies correlation of plasma concentration, history of methotrexate (NSC- 740). Cancer Chemotherapy Report, 54, 95–101.
- DOW, J. and BERG, C., 1995, Stereoselectivi ty of the carbonyl reduction of dolasetron in rats, dogs and humans. Chirality,, 7, 342–348.
- DOW, J., DI FRANCESCO, G. F. and BERG, C., 1996, Comparison of the pharmacokinetics of dolasetron and its major active metabolite reduced dolasetron in dog. Journal of Pharmaceutical Sciences, 85, 685–689.
- GALVAN, M GITTOS M W., MILLER, R. C., MOSER, P. C., VAN G IERSBERGEN, P. L. M. and FOZARD, J. R., 1992, Dolasetron mesilate (MDL 73,147EF), a potent anti-emetic 5-HT 3 receptor antagonist. British Journal of Pharmacology, 107, 449P.
- HAYES, K. A., B RENNAN, B., CHENERY, R. and HOUSTON, J. B., 1995, In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metabolism and Disposition, 23, 349–353.
- HOENER, B., 1994, Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharmaceutics and Drug Disposition, 15, 295–304.
- HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
- HUEBERT, N. D., SCHWARTZ, J.-J., H INZE, C. and H AEGELE K. D., 1994, Bioavailability and the effect of food on the pharmacokinetics of dolasetron mesilate and its active metabolite, MDL74156, in man. British Journal of Clinical Pharmacology, 37, 120P–121P.
- HUEBERT, N. D., S CHWARTZ, J.-J., ZEIDLER, L., S CHWACH, V. and H AEGELE, K. D., 1996, Simultaneous measurement of dolasetron and its major metabolite, MDL74156, in human plasma and urine. Journal of Chromatography B: Biomedical Applications (in press).
- HUSSEY, E. K., Doc, K. H., D ANIEL, M. J., HALL, S. T., HARKER, A. J. and EVANS, G. L., 1994, Interspecies scaling and pharmacokinetic parameters of 3TC in humans. Journal of Clinical Pharmacology, 34, 975–977.
- INGS, R. M. J., 1990, Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica, 20, 1201–1231.
- KRIS, M G., GRUNBERG, S. M GRALLA, R. J., BALTZER, L., ZARETSKY, S., LIFSEY, D., TYSON, L. B., S CHMIDT, L. and H AHNE W. F., 1994, Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Journal of Clinical Oncology, 12, 1045–1049.
- LAVE, T., SCHMITT - HOFFMANN, A. H., C OASSOLO, P., VALLES, B., UBEAUD, G., BA, B., BRANDT, R. and CHOU, R. C., 1995, A new extrapolation method from animal to man: application to a metabolized compound, mofarotene. Life Sciences, 56, 473–478.
- LAVE, T., COASSOLO, P., UBEAUD, G., BRANDT, R., S CHMITT, C., DUNN, S., JAECK, D. and C HOU, R. C., 1996a, Interspecies scaling of Bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharmaceutical Research 13, 97–101.
- LAVE, T., D UPIN, S., S CHMITT, M. et al., 1996b, Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransfera se (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica, 26, 839–851.
- MAHMOOD, I. and B ALIAN, J. D., 1996, Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. Journal of Pharmaceutical Sciences, 85, 411–414.
- MORDENTI, J., 1986, Man versus beast: pharmacokinetic scaling in mammals. Journal of Pharmaceutical Sciences, 75, 1028–1040.
- RANE, WILKINSON, G. R. and S HAND, D. G., 1977, Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics, 200, 420–424.
- REITH, M. K., S PROLES, G. D. and C HENG, L. K., 1995, Human metabolism of dolasetron mesylate, a5-HT 3 receptor antagonist. Drug Metabolism and Disposition, 23, 806–812.
- SANWALD P., DAVID, M. and Dow, J., 1996a, Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron: comparison with other indole containing 5-HT 3 antagonists. Drug Metabolism and Disposition, 24, 602–609.
- SANWALD P., DAVID, M. and Dow, J., 1996b, The use of electrospray ionization-liquid chromatography-mass spectrometry to study the role of CYP2D6 in the in vitro metabolism of 5- hydroxytryptami ne receptor antagonists. Journal of Chromatography B. Biomedical Applications, 678, 53–61.
- SANWALD P., H UEBERT, N. D. and H AEGELE K. D., 1994, Simultaneous measurement of the major metabolites of dolasetron mesilate in human urine using solid-phase extraction and high-performance liquid chromatography. Journal of Chromatography B.• Biomedical Applications, 661, 101–107.
- SAWADA, Y., HANANO, M., SUGIYAMA, Y. and I GA, T., 1984, Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmaceutics, 12, 241–261.
- UBEAUD, G., SCHMITT, C., JAECK, D., LAVE, T. and C OASSOLO, P., 1995, Bosentran, a new endothe lin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vitro and in vivo data. Xenobiotica, 25, 1381–1390.
- WILKINSON, G. R., and SHAND, D. G., 1975, A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics, 18, 377–390.
- ZOMORODI, K., CARLILE, D. J. and HOUSTON, J. B., 1995, Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica, 25, 907–916.